Your session is about to expire
← Back to Search
GEM00220 for Septic Shock (AMETHYST Trial)
AMETHYST Trial Summary
This trial will test whether a certain type of cell can help treat septic shock, a dangerous complication from infection.
AMETHYST Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAMETHYST Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AMETHYST Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have any type of cancer, except for non-melanoma skin cancer, that needed treatment in the past year.You have a serious lung condition with high carbon dioxide levels or need to use oxygen at home.You have dysfunction in one or more organs in your body.
- Group 1: Treatment arm - Dose Cohort 4
- Group 2: Treatment arm - Dose Cohort 3
- Group 3: Treatment Arm - Dose Cohort 1
- Group 4: Treatment arm - Dose Cohort 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there vacancies still open for potential participants in this trial?
"This medical trial is still open for participants. It was initially posted on the 8th of November 2021 and was revised most recently on November 16th 2022, per clinicaltrials.gov."
How many individuals are eligible to participate in this research experiment?
"Affirmative. Clinicaltrials.gov reflects that this clinical trial is still searching for 21 volunteers across three sites, with the initial posting dating back to August 11th 2021 and the last modification occuring on November 16 2022."
Can GEM00220 be used without any substantial risks to users?
"As a Phase 1 trial, the safety of GEM00220 has been determined to be at level 1 as there is limited evidence confirming both its efficacy and safety."
Share this study with friends
Copy Link
Messenger